Company NervGen Pharma Corp.

Equities

NGEN

CA64082X2032

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Quarterly revenue - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 03:59:58 2024-04-18 pm EDT			5-day change	1st Jan Change
2 ^CAD	+1.01%		-6.10%	-25.93%

Apr. 17	NervGen Reports FY 2023 Net Loss of $0.38 Per Share, Provides Operations Update	MT
Apr. 17	NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimerâs disease (AD) and multiple sclerosis (MS). Its NVG-291 is a therapeutic peptide, which is a mimetic of the intracellular domain of protein tyrosine phosphatase, a cell surface receptor known to interact with chondroitin sulfate proteoglycans (CSPGs) and to be involved in the regulation of neuroplasticity and central nervous system repair. The Company has two wholly owned subsidiaries, including NervGen US Inc. and NervGen Australia Pty Ltd.

Managers	Title	Age	Since
William Radvak FOU	Founder	61	17-01-18
Michael Kelly CEO	Chief Executive Officer	59	23-04-09
Bill Adams DFI	Director of Finance/CFO	62	20-02-23
Daniel Mikol CTO	Chief Tech/Sci/R&D Officer	-	21-05-04
Adam Rogers BRD	Director/Board Member	-	22-07-13

Members of the board	Title	Age	Since
Randall Kaye BRD	Director/Board Member	62	20-10-27
Brian Bayley BRD	Director/Board Member	71	18-05-15
William Radvak FOU	Founder	61	17-01-18
Michael Kelly CEO	Chief Executive Officer	59	23-04-09
Harold Punnett FOU	Founder	67	17-01-18
John Thompson BRD	Director/Board Member	57	22-04-12
John Ruffolo BRD	Director/Board Member	-	23-10-16
Glenn Ives BRD	Director/Board Member	62	21-08-31
Adam Rogers BRD	Director/Board Member	-	22-07-13
Krista McKerracher BRD	Director/Board Member	-	21-08-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	69,927,649	53,893,753 ( 77.07 %)	0	77.07 %

Name	Equities	%	Valuation
Pfp Biosciences Holdings LLC 21.64 %	12,879,149	21.64 %	21 M $
William Radvak 2.365 %	1,407,500	2.365 %	2 M $
Harold Punnett 1.891 %	1,125,532	1.891 %	2 M $
Brian Bayley 0.6722 %	400,000	0.6722 %	644 000 $
Bill Adams 0.2619 %	155,820	0.2619 %	250 870 $
Michael Kelly 0.2419 %	143,957	0.2419 %	231 771 $
John Ruffolo 0.1183 %	70,407	0.1183 %	113 355 $
Glenn Ives 0.0983 %	58,511	0.0983 %	94 203 $
Randall Kaye 0.0168 %	10,000	0.0168 %	16 100 $
Adam Rogers 0.0168 %	10,000	0.0168 %	16 100 $

NervGen Pharma Corp.

112-970 Burrard Street Unit 1290

V6Z 2R4, Vancouver

+778-731-1711

http://www.nervgen.com

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2 CAD

Average target price

5 CAD

Spread / Average Target

+150.00%

Consensus

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
NERVGEN PHARMA CORP.	-25.93%	102M
IQVIA HOLDINGS INC.	-1.82%	41.35B
LONZA GROUP AG	+42.44%	40.38B
MODERNA, INC.	+2.56%	39.05B
CELLTRION, INC.	-12.11%	26.67B
ICON PUBLIC LIMITED COMPANY	+3.09%	24.07B
ALNYLAM PHARMACEUTICALS, INC.	-24.16%	18.36B
MEDPACE HOLDINGS, INC.	+22.12%	11.6B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.74%	11.68B
UNITED THERAPEUTICS CORPORATION	+7.75%	11.15B

Other Biotechnology & Medical Research